申请人:Pfizer Inc.
公开号:US05686434A1
公开(公告)日:1997-11-11
This invention relates to 3-aryl-2-isoxazoline compounds which are selective inhibitors of phosphodiesterase type IV (PDE.sub.IV). The 3-aryl-2-isoxazolines are useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease, psoriasis, allergic rhinitis, dermatitis, shock, atopic dermatitis, rheumatoid arthritis and osteoarthritis. This invention also relates to pharmaceutical compositions useful therefor.
这项发明涉及3-芳基-2-异噁唑啉化合物,这些化合物是磷酸二酯酶IV型(PDE.sub.IV)的选择性抑制剂。3-芳基-2-异噁唑啉在治疗艾滋病、哮喘、关节炎、支气管炎、慢性阻塞性肺病、牛皮癣、过敏性鼻炎、皮炎、休克、特应性皮炎、类风湿性关节炎和骨关节炎方面具有用途。该发明还涉及用于此类用途的药物组合物。